Madecassoside
Catalog No: CFN99913
Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4, which has antioxidant, anti-inflammatory, anti-apoptosis, wound-healing, and neuroprotective activities, It may have cardioprotective effects in LPS-mediated through inhibition of ERK, p38, and NF-κB activity, it inhibited the pro-inflammatory mediators, including COX-2 expression, PGE2 production, TNF-αand IL-6 levels and the up-regulation anti-inflammatory molecule IL-10.
Hydroxysafflor yellow A
Catalog No: CFN99950
Hydroxysafflor yellow A(H-A) possesses hepatoprotective, anti-inflammatory, and anti-tumor activities, it can effectively protect the liver of rats from long-term alcohol injury, which relates with the enhanced antioxidant capacity of liver tissues and inhibition of TGF-β1 expression, it also inhibited angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. H-A also can provide protection to H9c2 cardiomyocytes against A/R-induced apoptosis by the upregulation of HO-1 expression through the PI3K/Akt/Nrf2 signaling pathway.
Pseudoginsenoside F11
Catalog No: CFN99963
Pseudoginsenoside F11, a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5. It possesses significant neuroprotective activity, has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice; it also antagonizes the development of analgesia tolerance to morphine and blocks the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC.
